Liran Belenzom headshot

When fundraising make sure your deck is solid, the story is solid and you have the right investor

Philip Bliss |

Liran Belenzon is the CEO of BenchSci, a biomedical artificial intelligence company he co-founded in 2016. BenchSci’s mission is to exponentially increase the speed and quality of life-saving research, by empowering scientists to design more successful experiments.

BenchSci has grown to over 300 people and raised more than $200 million from top investors, including Google’s Gradient Ventures and F-Prime. BenchSci works with 15 of the world’s top 20 pharma companies, over 4,300 academic institutions, and more than 40,000 scientists. As CEO, Liran strives to inspire people to be the best version of themselves and to make a positive impact on the world. Liran emigrated to Toronto, Canada, and completed his MBA at The University of Toronto’s Rotman School of Management. While at Rotman, he worked in the Creative Destruction Lab (CDL), where he met BenchSci co-founders Tom Leung, David Chen, and Elvis Wianda. As a passionate entrepreneur, Liran envisions a future where Toronto and Canada are global leaders in entrepreneurship.


Entrepreneurs are the backbone of Canada’s economy. To support Canada’s businesses, subscribe to our YouTube channel and follow us on FacebookInstagramLinkedIn and Twitter.

Want to stay up-to-date on the latest #entrepreneur podcasts and news? Subscribe to our bi-weekly newsletter

Related Podcasts

Why Entrepreneurs Must Believe in Their Unique Value

As an entrepreneur. You have to believe that you have something better and different to offer. With over 20...

Read More

Why Every Marketer Needs to Get Up to Speed on AI

Ryan Walker is CEO and Managing Partner of Central Station, an independent creative agency based in Toronto. Central Station...

Read More

From Big Tech to Healthcare: Zameer Rizvi’s Mission to Improve Patient Care

Ontario-based Zameer Rizvi is the Founder & CEO of Odesso and has a great entrepreneurial story. Zameer has two...

Read More

Join Our Newsletter

Subscribe to receive info on our latest news and episodes

Subscribe